A published work Lancet HIV Indicates that HIV-2 is more pathogenic than previously shown. Recent findings suggest that early treatment should be applied to all patients with HIV, not just those with HIV-1.
De The study is unique because we follow the cohort that the participants often work with over a long period of time, which allows us to monitor the progression of the disease and to determine when patients are infected with HIV and to monitor the progression of the disease. medical microbiologist Joakim Esbjörnsson, researcher and researcher, HIV-2 infected those who develop AIDS cause AIDS.
HIV-1 and HIV-2 virus species are closely related, but vary according to their spread to the world. HIV-1, globally spread, seen as a lighter variant of HIV, is commonly prevalent in West Africa.
The study is the first to present reliable estimates of the time interval between HIV infection and HIV-related death for AIDS or HIV-2. The researchers watched 4 900 people in Guinea-Bissau in a cohort study of annual examinations, including blood tests conducted between 1990 and 2013 for 23 years. The study also compared HIV-1 infected individuals with HIV-negative individuals in the same cohort. The data from the study shows that HIV-2 patients develop HIV-related infections and AIDS in nearly the same way as HIV-1, but the process is slower over time.
In previous studies, it was stated that HIV-2 patients would have a normal life-span without HIV-1 disease, even without antiretroviral treatment, without HIV-related complications. More than 98 percent of AIDS cases. Even WHO's recommendations for treatment suggest that it is unclear to offer treatment to HIV-2 patients.
Uz As HIV-2 does not cause disease in the same way as HIV-2, there is a common belief in the field of public health as well as researches on HIV: we want to eliminate this belief and change its views. International treatment recommendations, "says Joakim Esbjörnsson.
A similar study has not been done since the course of HIV disease is long and it is likely that it would not be possible to do something similar again. Joakim Esbjörnsson believes that the difficulty of studying HIV-2 over time is one of the reasons for the general uncertainty about what aggressive HIV-2 is, and also has a dominant view of when to initiate treatment.
Another specific problem with HIV-2 is that most people infected with HIV-2 do not have measurable virus levels in the blood. This increased the uncertainty about when and when treatment would be performed. Specialist in infectious diseases at Lund University and infection clinic at Skåne University Hospital in Lund.
In Moreover, HIV-2 is mostly seen in West Africa, the poorest region in the world, which is characterized by low levels of investment and frequent political instability, which makes research and development even more difficult in the region. ğinde Commercial interest has not been equally strong in the development of diagnosis and treatment, m says Fredrik Månsson, a clinical infectious disease researcher at Lund University, and a specialist in the infection clinic at Skåne University Hospital in Malmö.
Researchers want to do more research on the HIV field and do research on the field to better understand the differences between the two types. Among other things, a treatment study is needed over time to verify the usefulness of early treatment in HIV-2 patients.
The study is the collaboration between the health center of the police authority in Lund University, Örebro University, Bissau and the national public health laboratory researchers and staff in Guinea-Bissau. Rather, it has been conducted by researchers from Lund University and Skåne University Hospital, including Joakim Esbjörnsson, Fredrik Månsson and Hans Norrgren, who have had long-term HIV research both in Sweden and in countries that have been severely affected by HIV.
The study was supported by Sida and Sarec from 1990 to 2011.
Materials supplied by Lund University. Note: The content can be edited for style and length.